Drug Profile

BA 1302

Alternative Names: BA-1302

Latest Information Update: 26 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer; Non-small cell lung cancer
New Molecular Entity Yes

Phase I Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer
Preclinical Solid tumours

19 Jun 2026 Preclinical trials in Solid tumours in USA (Parenteral) prior to June 2026 (Shandong Boan Biotechnology pipeline, June 2026)
19 Jun 2026 US FDA approves IND application for BA 1302 in Solid tumours prior to June 2026 (Shandong Boan Biotechnology pipeline, June 2026)
19 Jun 2026 Shandong Boan Biotechnology plans a phase I trial for Solid tumours in USA (Shandong Boan Biotechnology pipeline, June 2026)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com